NZ732704A - Quinoline carboxamides for use in the treatment of leukemia - Google Patents
Quinoline carboxamides for use in the treatment of leukemiaInfo
- Publication number
- NZ732704A NZ732704A NZ732704A NZ73270415A NZ732704A NZ 732704 A NZ732704 A NZ 732704A NZ 732704 A NZ732704 A NZ 732704A NZ 73270415 A NZ73270415 A NZ 73270415A NZ 732704 A NZ732704 A NZ 732704A
- Authority
- NZ
- New Zealand
- Prior art keywords
- leukemia
- treatment
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ732704A true NZ732704A (en) | 2022-01-28 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ732704A NZ732704A (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (enExample) |
| EP (1) | EP3180005B1 (enExample) |
| JP (1) | JP6715833B2 (enExample) |
| KR (1) | KR102525805B1 (enExample) |
| CN (1) | CN107072989B (enExample) |
| AU (1) | AU2015348778B2 (enExample) |
| BR (1) | BR112017009854B1 (enExample) |
| CA (1) | CA2967112C (enExample) |
| EA (1) | EA031643B1 (enExample) |
| ES (1) | ES2663836T3 (enExample) |
| IL (1) | IL252174B (enExample) |
| MX (1) | MX379401B (enExample) |
| NZ (1) | NZ732704A (enExample) |
| PL (1) | PL3180005T3 (enExample) |
| WO (1) | WO2016078921A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168070A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| AU2021313388A1 (en) | 2020-07-23 | 2023-01-19 | Erasmus University Medical Center Rotterdam (Erasmus Mc) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| PL4277628T3 (pl) * | 2021-01-18 | 2026-02-09 | Active Biotech Ab | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
| JP2024520307A (ja) | 2021-05-25 | 2024-05-24 | アクティブ バイオテック エイビー | 複数のタスキニモド粒子およびその使用 |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| EP2590949B1 (en) | 2010-07-09 | 2015-11-25 | Active Biotech AB | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791099A1 (ru) | 2017-10-31 |
| KR20170083121A (ko) | 2017-07-17 |
| MX2017006110A (es) | 2017-07-27 |
| IL252174B (en) | 2021-02-28 |
| AU2015348778A1 (en) | 2017-06-29 |
| BR112017009854B1 (pt) | 2022-08-23 |
| EP3180005A1 (en) | 2017-06-21 |
| KR102525805B1 (ko) | 2023-04-25 |
| PL3180005T3 (pl) | 2018-06-29 |
| CN107072989B (zh) | 2020-07-03 |
| ES2663836T3 (es) | 2018-04-17 |
| BR112017009854A2 (pt) | 2018-01-16 |
| MX379401B (es) | 2025-03-11 |
| CN107072989A (zh) | 2017-08-18 |
| US10300053B2 (en) | 2019-05-28 |
| CA2967112A1 (en) | 2016-05-26 |
| JP2017534652A (ja) | 2017-11-24 |
| JP6715833B2 (ja) | 2020-07-01 |
| WO2016078921A1 (en) | 2016-05-26 |
| IL252174A0 (en) | 2017-07-31 |
| EP3180005B1 (en) | 2017-12-27 |
| CA2967112C (en) | 2023-05-16 |
| EA031643B1 (ru) | 2019-01-31 |
| AU2015348778B2 (en) | 2020-12-24 |
| US20170319568A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| ZA201701299B (en) | Glycosidase inhibitors | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| EP3209653A4 (en) | Process for the preparation of (r,s)-nicotine | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| AU2015352440B2 (en) | Compounds | |
| PH12016501252A1 (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| GEAP201914284A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| MX379401B (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| ZA201802399B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| EP3125876B8 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| WO2016040313A3 (en) | Methods of treating cancer comprising administering a ppar-gamma agonist | |
| LT3119752T (lt) | 3,4-diamino-6-chlorpirazin-2-karboksamido junginiai, skirti enac sąlygotų ligų gydymui | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
| UA90817U (uk) | Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями | |
| UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол | |
| UA90821U (uk) | Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20221006 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2024 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20231005 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2025 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20241011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20251008 |